Intermec, Inc. Form 4 May 27, 2011

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

(Last)

1.Title of

Security

(Instr. 3)

1. Name and Address of Reporting Person \* YOST LARRY D

(First) (Middle)

4531 CARRARA COURT

(Street)

JACKSONVILLE, FL 32224

2. Issuer Name and Ticker or Trading Symbol

Intermec, Inc. [IN]

3. Date of Earliest Transaction

(Month/Day/Year) 05/25/2011

4. If Amendment, Date Original

Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to

**OMB** 

Number:

Expires:

response...

Estimated average

burden hours per

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

Issuer

(Check all applicable)

X\_ Director 10% Owner Officer (give title Other (specify

6. Individual or Joint/Group Filing(Check

below)

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(City) (State) (Zip)

2. Transaction Date 2A. Deemed

(Month/Day/Year) Execution Date, if

(Month/Day/Year)

4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

Code V Amount (D) Price

(A)

or

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct

7. Nature of Indirect (D) or Indirect Beneficial Ownership

(9-02)

(Instr. 4) (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(Instr. 3 and 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion Security or Exercise (Instr. 3) Price of

3. Transaction Date 3A. Deemed (Month/Day/Year)

Execution Date, if (Month/Day/Year)

5. Number of 4 TransactionDerivative Code Securities (Instr. 8) Acquired (A)

6. Date Exercisable and **Expiration Date** (Month/Day/Year)

7. Title and Ar Underlying Se (Instr. 3 and 4)

	Derivative Security	or Disposed (D) (Instr. 3, 4, and 5)			of			
			Code	V (A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 11.94	05/25/2011	A	17,858		05/25/2011(1)	05/25/2018	Common Stock
Restricted Deferred Stock Units	<u>(2)</u>	05/25/2011	A	6,700		08/08/1988(3)	08/08/1988	Common Stock

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
<b>FB</b>	Director	10% Owner	Officer	Other	
YOST LARRY D 4531 CARRARA COURT JACKSONVILLE, FL 32224	X				

## **Signatures**

By: Mary Brodd For: Larry D Yost 05/27/2011

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable of 4,464 shares on 5/25/2011, 4,464 shares on 7/4/2011, 4,464 shares on 10/3/2011 and 4,466 shares on 01/1/2012.
- (2) Each restricted deferred stock unit represents a contingent right to receive one share of Intermec common stock.
- The restricted deferred stock units fully vest as of the date of the 2012 Annual Meeting of Stockholders. Grants made in prior years are
- (3) fully vested in accordance with their terms. Restricted deferred stock units are deferred under the Intermec Director Deferred Compensation Plan and are converted into shares of common stock in the January following the year of the reporting person's termination of services as a director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. le="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"> TABLE OF CONTENTS

Page

#### PART I—FINANCIAL INFORMATION

Item 1. Financial Statements 1

Reporting Owners 2

	Condensed Consolidated Balance Sheets at March 31, 2018 (Unaudited) and December 31, 2017	1
	Condensed Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2018 and 2017	2
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2018 and 2017	3
	Notes to Condensed Consolidated Financial Statements (Unaudited)	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	31
Item 4.	Controls and Procedures	31
PART I	I—OTHER INFORMATION	
Item 1.	Legal Proceedings	32
Item 1A	Risk Factors	32
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	32
Item 3.	<u>Defaults Upon Senior Securities</u>	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	<u>Exhibits</u>	33
	Signatures	34
	Index to Exhibits	35

-i-

#### **Table of Contents**

### INNOVUS PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

March 31, 2018

December

31, 2017

ASSETS (Unaudited)

#### Assets:

Cash	\$4,923,796	\$1,564,859
Accounts receivable, net	195,242	68,259
Prepaid expense and other current assets	333,136	363,080
Inventories	1,648,730	1,725,698
Total current assets	7,100,904	3,721,896
Property and equipment, net	203,385	62,454
Deposits	20,881	20,881
Goodwill	952,576	952,576
Intangible assets, net	4,115,624	4,273,099
Total assets	\$12,393,370	\$9,030,906

### LIABILITIES AND STOCKHOLDERS' EQUITY

#### Liabilities:

Accounts payable and accrued expense	\$2,910,282	\$2,607,121
Accrued compensation	1,288,209	1,118,293
Deferred revenue and customer deposits	142,769	24,690
Accrued interest payable	11,671	3,648
Derivative liabilities – warrants	•	58,609
	-	
Contingent consideration	32,883	28,573
Short-term loan payable	32,775	65,399

Notes payable, net of debt discount of \$929,353 and \$437,355, respectively Total current liabilities	2,288,876 6,707,465	1,239,296 5,145,629
Accrued compensation – less current portion  Contingent consideration – less current portion	1,531,904 1,448,965	1,531,904 1,450,430
Total non-current liabilities	2,980,869	2,982,334
Total liabilities	9,688,334	8,127,963
Commitments and contingencies		
Stockholders' equity:		
Preferred stock: 7,500,000 shares authorized, at \$0.001 par value, no shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	-	-
Common stock: 292,500,000 shares authorized, at \$0.001 par value, 192,555,147 and 167,420,605 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	192,555	167,421
Additional paid-in capital		